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ABSTRACT

ARTICLE HISTORY

Gold nanoparticles (AuNPs) have been shown to enhance cancer radiotherapy (RT) gain by localizing the
absorption of radiation energy in the tumor while sparing surrounding normal tissue from radiation
toxicity. Previously, we showed that AuNPs enhanced RT induced DNA damage and cytotoxicity in MCF7
breast cancer cells. Interestingly, we found that cancer cells exhibited a size-dependent AuNPs intracel
lular localization (4 nm preferentially in the cytoplasm and 14 nm in the nucleus). We extended those
studies to an in vivo model and examined the AuNPs effects on RT cytotoxicity, survival and immunomo
dulation of tumor microenvironment (TME) in human triple negative breast cancer (TNBC) xenograft
mouse model. We also explored the significance of nanoparticle size in these AuNPs’ effects. Mice treated
with RT and RT plus 4 nm or 14 nm AuNPs showed a significant tumor growth delay, compared to
untreated animals, while dual RT plus AuNPs treatment exhibited additive effect compared to either RT or
AuNPs treatment alone. Survival log-rank test showed significant RT enhancement with 14 nm AuNP
alone; however, 4 nm AuNPs did not exhibit RT enhancement. Both sizes of AuNPs enhanced RT induced
immunogenic cell death (ICD) that was coupled with significant macrophage infiltration in mice pre
treated with 14 nm AuNPs. These results showing significant AuNP size-dependent RT enhancement, as
evident by both tumor growth delay and overall survival, reveal additional underlying immunological
mechanisms and provide a platform for studying RT multimodal approaches for TNBC that may be
combined with immunotherapies, enhancing their effect.
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Introduction
Radiation therapy (RT) as a standard of care for more than half
of all cancer patients,1,2 exerts its cytostatic and cytotoxic
effects via DNA damage. However, radiation ionizations are
random and do not discriminate between cancer cells and
surrounding normal tissue. Hence, RT efficiency is fundamen
tally limited by early and late side effects that profoundly affect
patients’ quality of life.3 In addition, RT cytotoxicity has been
a major limiting factor in maximizing deposited RT dose and
a significant obstacle in cancer treatment planning.4 Therefore,
one solution to these obstacles that has been an area of active
research is the enhancement of RT therapeutic ratio through
developing strategies for a delivery of higher RT doses to the
tumor itself, while minimizing damage to the surrounding
normal tissue.5 This can be achieved through modulating
a tumor response to RT by using radiosensitizers, such as
nanoparticles that increase the sensitivity of cancer cells to
irradiation.6 Particularly promising as radio-sensitizers are
NPs containing metals of high atomic number (Z) due to
their high absorption coefficient. The targeting of NPs to
tumor tissue coupled with the high stopping power of metals
compared to soft tissue increase the local radiation dose
deposition. Among metal NPs, gold NPs (AuNPs) have been
proposed as attractive radio-sensitizers due to the high Z of
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gold. Gold has a large photoelectric cross section and a high
probability of secondary electrons and associated free radicals
production.7 This photoelectric effect is most dominant at low,
kilo voltage (kV) energy levels where it causes a significant
increase in the absorbed radiation dose.8,9 On the other hand,
at clinically relevant x-ray energies at the megavoltage (MV)
range, the dominant physical event is Compton scattering that
is not expected to cause significant AuNP sensitization;10,11 but
observed RT enhancement at these energies is still significant
and has been explained by a combination of physical, chemical,
and biological mechanisms.10,12,13 Radiosensitization by
AuNPs remains an active area of research in the preclinical
setting,8,14–17 where experimentally measured dose enhance
ment was greater than predicted based on the mass attenuation
coefficients, confirming that mechanisms other than physical
are involved in AuNP radio-sensitization.18 Recent studies
indicated that oxidative stress in cells caused by reactive oxy
gen species generated by AuNPs in the absence of ionizing
radiation may account for radio-sensitization via biological
mechanisms.11,19,20 However, most AuNP studies remain
preclinical, awaiting clinical translation and biosafety
confirmation.13
Recent research showed that beside cytostatic and cytotoxic
effects, RT exhibits immunomodulatory effect on tumor
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microenvironment (TME) as well, an effect that has drawn
huge research interest. Radiation immunomodulation is
achieved through mechanisms such as immunogenic cell
death (ICD),21,22 tumor neoantigen presentation,23 cytokine
secretion and activation and priming of host antitumor
T cells.24 Therefore, RT may have potential to convert the
irradiated and damaged cancer cells into an in situ vaccine
and to stimulate immunogenicity of tumor microenvironment,
important for inducing antitumor immunity. In “immunolo
gically cold” cancers, such as very aggressive triple negative
breast cancer (TNBC), increase in tumor microenvironment
immunogenicity has been associated with a better prognosis as
a result of enhanced responses to chemotherapy and
immunotherapy.25
Particularly important in the RT immunomodulation pro
cess is ICD whereby signals such as calreticulin and nuclear
protein high-mobility group box-1 (HMGB-1) (a.k.a. damageassociated molecular patterns (DAMPs)) are generated.22,26
These signals are instrumental in initiating anti-tumor immu
nity. DAMPs trigger dendritic cell (DC) recruitment, antigen
uptake and presentation to CD8 + T cells and a consequent
adaptive long-term immunity,26 and have been explored as
potential prognostic breast cancer markers.27 However,
a direct link between RT regimen and ICD induction remains
elusive. It is also not clear if biological mechanisms involved in
AuNP mediated RT dose enhancement include changes in RT
immunomodulatory properties as well. Breast cancer (BC)
models have been frequently used in exploring the effects of
radiation therapeutics and recent work in syngeneic TNBC 4T1
mouse models explored RT potential in mediating immune
response elements such as CD8 + T cells28 and chemokine
secretion29. However, very few analyzed the AuNPs as RT
enhancer in TNBC MDA MB 231 model30 and there has
been no exploration on immunological effects. Since TNBC is
one of the most aggressive forms of BCs with extremely low
rate of survival and very limited treatment options,31 we seek to
develop strategies for improving TNBC radiation therapy out
come. In this study, we used human MDA MB 231 TNBC
mouse xenograft model to investigate the potential of AuNPs
to enhance radiotherapy and modulate immunological proper
ties of TME. We used two different core sizes of AuNPs, 4 nm
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and 14 nm, because they are within the size range of suggested
optimums for most efficient cellular uptake, accumulation and
distribution within the tumors32 and least possibility for sys
temic toxicity.33. We examined the capacity of AuNPs to
enhance RT effects in vivo in MDA MB 231 xenograft mouse
model. First, we qualitatively confirmed the cellular uptake and
intracellular localization of 4 and 14 nm AuNPs by transmis
sion electron microscopy (TEM). We next showed that both
4 nm and 14 nm size AuNPs when delivered intratumorally
enhanced RT effects that lead to a decrease in tumor volume,
while overall increase in survival was achieved only with 14 nm
AuNPs. Interestingly, AuNPs effects were accompanied by
changes in the expression of immunologically relevant markers
such as calreticulin and macrophage infiltration. The results of
this study indicate that local intratumor delivery of AuNPs is
a promising strategy for developing AuNP radio-sensitization
clinical protocols. In addition, these data provide valuable
information on the potential role of immunological processes
in the mechanisms of AuNP mediated RT enhancements.

Results
AuNP uptake by MDA MB 231 cells
Cellular uptake of AuNPs can be achieved via passive translo
cation across the cell membrane or through active
endocytosis34 and it can be influenced by nanoparticle size,
shape, surface chemistry and dose.35 We performed
a qualitative analysis of the cellular uptake of 4 nm AuNPs
and 14 nm AuNPs by the MDA MB 231 breast cancer cells
using TEM. Cells were incubated with 4 nm AuNP or with
14 nm AuNP for 2 h, after which cells were extensively washed
to remove excess or any surface-attached nanoparticles. TEM
image analysis revealed numerous high electron densitystaining particles inside the cells incubated with AuNPs
(Figure 1(a, Figure 1b)). In MDA MB 231 cells incubated
with 4 nm AuNPs, nanoparticle clusters were detected
throughout the cytoplasm with the majority of AuNPs trapped
within the membranous structures/vesicles (Figure 1(a)). Most
of these vesicles were located in the vicinity of nucleus (Nu),
but some were found in the proximity of mitochondria (MT)

Figure 1. Cellular uptake of AuNPs by MDA-MBA 231 cells. (A) TEM images of MDA MB 231 cells exposed to 4 nm AuNPs showing the internalized high electron densitystaining particles inside vesicles (red arrows). (B) TEM images of MDA MB 231 cells incubated with 14 nm AuNPs where some AuNPs were detected inside the
cytoplasmic vesicles (red arrows), while portion some AuNPs were found within the nuclei (red arrows; bottom panels). (C) TEM image of MDA MB 231 cells not exposed
to AuNPs (control).
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and endoplasmic reticulum (ER). Magnified images of vesicles
containing AuNPs are shown in the bottom panels of Figure 1
(a). Similar intracellular distribution was observed in MDA MB
231 cells incubated with 14 nm AuNPs (Figure 1(b)). However,
sparse, less aggregated granules of high electron density were
also observed in the nuclei, indicative of nuclear AuNP uptake,
which was not observed in cells incubated with 4 nm AuNP
(bottom panels, Figure 1(b)). Images of control cells that were
not treated with AuNPs are shown in Figure 1(c). Altogether,
TEM data demonstrated MDA MB 231 cellular uptake of
AuNPs with a potential nanoparticle size-dependent differen
tial intracellular localization. In addition, MDA MB 231 cell
morphology exhibited unremarkable subcellular compart
ments indicating that AuNPs did not alter MDA MB 231 cell
activity and metabolically active status.36
Therapeutic efficacy and toxicity in vivo
Treatment efficacy was measured by a percentage change in
tumor volume (Figure 2). Mice treated with RT and RT plus 4
or 14 nm AuNP showed a significant tumor growth delay
starting at days 7 and 4, respectively, compared to their
untreated controls (p < .05). Mice receiving 4 or 14 nm
AuNP also exhibited significant tumor growth delay in AuNP
plus RT treatment group, compared to RT alone treatment
(p < .05) that was observed on day 30 in mice receiving 4 nm
AuNP and on day 19 and 23 in mice receiving 14 nm AuNP
(Figure 2(a,Figure 2b)). Interestingly, 7 days post-treatment
with 4 nm AuNP alone mice showed significant tumor growth
delay, compared to the untreated controls. Similarly, in ani
mals treated with 14 nm AuNP alone significant tumor growth

delay, compared to the untreated controls was observed start
ing at day 4 and this effect was of the similar magnitude and
pattern as observed in animals treated with RT alone and at day
26 the effect was the same as observed in RT + AuNP treatment
group (Figure 2(a,Figure 2b).
Systemic toxicity was evaluated by calculating the percen
tage of body weight loss (Figure 3). There were significant
changes in body weight, but their magnitude was relatively
minor, less than ± 10% throughout the course of the entire
study. In animals treated with 4 nm AuNP alone, a significant
difference in the percentage of body weight change (loss of
weight) was observed compared to that of the control, nontreated group at days 11 and 15 and in animals treated with RT
+ 4 nm AuNP combination at days 4, 7, 11 and 15 compared to
that of the control, non-treated group (p < .05)(Figure 3(a)).
However, in animals treated with 14 nm AuNP alone, body
weight was significantly higher at day 4,7 and 11, compared to
the control, non-treated animals and compared to RT treat
ment group at days 4, 11, 19 and 23 (p < .05), indicating less
toxicity in the presence of 14 nm AuNPs (Figure 3(b)).
Survival analysis using log-rank (Mantel-Cox) test indicated
significant survival differences among treatment groups (Figure 4
(a,b)). Further comparison revealed significant increases in survi
val in the RT group compared to untreated controls (p < .005) as
well as an increase in survival of groups treated with RT + 4 nm
AuNP and RT + 14 nm AuNP, compared to the control groups
(p = .0018 and p < .0001, respectively, Table 1 and Table 2).
Significant potentiation of RT survival effect was achieved when
RT was combined with 14 nm AuNPs (p = .0006) (Table 2), while
4 nm AuNP was not effective. Furthermore, treatment with 14 nm
AuNPs alone significantly increased the survival compared to RT

Figure 2. Effect of AuNPs on RT induced tumor growth delay. Primary tumor volumes were measured at 3–4 days intervals by calipers and calculated using the formula:
4∕3π x Length x Width x ((Length + Width)/2)/8. Percentage of tumor volume change over time in mice treated with 4 nm AuNPs (n = 5) (A) and 14 nm AuNPs (n = 5–9)
(B). Data represent mean ± SEM *p < .05 compared to control; **p < .05 compared to RT alone.

Figure 3. Effect of AuNPs and RT on body weight change. (A) Percentage body weight change in animals receiving 4 nm AuNP. Animals were weighed two times per
week; Data represent mean ± SEM (n = 5). *p < .05 for 4 nm AuNP alone compared to control; **p < .05 for RT compared to control; ***p < .05 for RT + 4 nm AuNP
compared to control (B) Percentage body weight change in animals receiving 14 nm AuNP. Animals were weighed two times per week; Data represent mean ± SEM
(n = 5–9). *p < .05 for 4 nm AuNP alone compared to control; **p < .05 for 4 nm AuNP alone compared to RT alone.
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Figure 4. Effect of AuNPs and AuNP enhanced RT on survival. Survival analysis by log rank Mantel Cox test. Compared to untreated control groups, significantly
prolonged survival was achieved for the following groups: RT alone and RT + 4 nm AuNP (A), and RT alone, 14 nm AuNP alone and RT + 14 nm AuNP (B). Compared to
RT alone treatment groups, significantly prolonged survival was achieved for the following groups: 14 nm AuNP alone and RT + 14 nm AuNP and (B).

Table 1. Survival analysis - 4nm AuNP experiments.
4 nm AuNP experiments
Comparison
95% CI of ratio
RT vs control
0.4240 to 5.880
RT + AuNP vs control 0.4240 to 5.880

Table 2. Survival analysis - 14nm AuNP experiments.
14 nm AuNP
Comparison
95% CI of ratio
experiments
RT vs control
0.6245 to
5.836
AuNP vs control
0.6347 to
8.802
RT + AuNP vs control
0.6843 to
8.165
RT vs AuNP
0.2432 to
2.682
RT vs RT + AuNP
0.2642 to
2.469

AuNP effects on TME immunological properties
p
0.0142
0.0018

p
0.0009
0.0019
<0.0001
0.0014
0.0006

alone (p = .0014). Median survival and “n” values are shown in
Table 3.
Intratumor distribution of injected AuNPs was macrosco
pically determined in tumor tissues collected at day 26 of the
study. Analysis of harvested tumor sections revealed rather
heterogeneous distribution of AuNPs within the tumor.
However, 14 nm AuNPs more evenly dispersed within the
tissue, while 4 nm AuNPs congregated in visible clusters
(Figure 5(a,Figure 5b). Figure C shows tissue from control
animals.

Table 3. Median Survival.
control AuNP RT RT + AuNP
4 nm AuNP experiments

n
Median survival
14 nm AuNP experiments
n
Median survival

5
19
5
11

5
23
5
26

5
30
8
21

5
30
9
26

We next investigated whether the observed therapeutic effects
were associated with changes in tumor microenvironment immu
nological properties. Collected tumor tissues were analyzed by
immunohistochemistry for the expression of activated, cleaved
Caspase 3, calreticulin and macrophage infiltration. These para
meters were previously shown to be associated with programmed
cell death and ICD.37 Tissue staining for the cleaved Caspase 3
revealed higher percentage of positive stain in mice receiving RT
alone, as well as RT + 4 nm AuNPs and RT + 14 nm AuNPs,
compared to control non-treated animals (p < .05). However,
addition of AuNPs to RT treatment did not induce significant
increase in cleaved Caspase 3 expression, compared to RT treat
ment alone. Although the addition of 4 nm AuNP exhibited
potentiation of RT effect, this increase was not statistically signifi
cant compared to RT alone. Percent of cleaved Caspase 3 positive
stain in animals treated with either 4 nm AuNPs or 14 nm AuNPs
was similar as observed in control, non-treated animals (Figure 6
(a)). Representative digital microscopy images of cleaved Caspase
3 immunohistology staining are shown in Figure 6(b). Tissue
analysis of calreticulin expression revealed increase in the percen
tage of positive cells in animals receiving RT alone as well as 14 nm
AuNP alone (p < .05). In mice receiving the combination of 4 nm
AuNPs + RT or 14 nm AuNPs, this effect was further significantly
potentiated in comparison to the effect of RT alone (p < .05)
(Figure 6(c)). Representative digital microscopy images of tissues
stained with anti-calreticulin antibody are shown in Figure 6(d).
Lastly, macrophage infiltration in tumor tissue sections were ana
lyzed by staining for the F4/80 pan macrophage marker (Figure 6
(e)). No difference was observed in animals receiving single treat
ment of RT, 4 nm AuNPs or 14 nm AuNPs compared to nontreated, control group of animals. However, the addition of 14 nm
AuNP to RT treatment significantly increase macrophage infiltra
tion compared to control non-treated group of animals as well as

Figure 5. Intratumoral distribution of administered AuNP. Macroscopic images of MDA MB 231 transplanted tumors excised at day 26. Tumors extracted from animals
receiving 14 nm AuNP (A), 4 nm AuNPs (B) and animals that did not receive any AuNP (C).
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Figure 6. Effect of AuNPs and AuNP enhanced RT on tissue expression of cleaved Caspase 3, Calreticulin and macrophage infiltration. Immunohistochemistry analysis of
the percentage of positive stain for cleaved Caspase 3 (A) and F 4/80 (E) and for the percentage of cells positive for Calreticulin (C). Digitalized tissue stains were
evaluated for staining extent and intensity by QuPath software custom made application. Data expressed as mean + SEM (n = 5). *p < .05 compared to control; **p < .05
compared to RT alone. Corresponding representative images of tissue stains are shown in panels B, D and F.

compared to animals treated to RT alone. Representative digital
microscopy images of F4/80 staining are shown in Figure 6(b).

Discussion
Triple negative breast cancer (TNBC) is the most aggressive BC
form that accounts for 15–20% of all the BCs.38 When diag
nosed, TNBC is typically presented as a high-grade tumor with
a high rate of distant metastases39 and a very low rate of
a disease-free and overall survival (<18 months).31 Patients
with TNBC have very limited treatment options that usually
include chemotherapy and radiation; however, they very often
fail due to developed resistance to these therapies.40 TNBC
radiation resistance in particular, was demonstrated to be
linked to the slow tumor cell cycle progression that allows
time for radiation induced DNA damage to be efficiently
repaired.41 Thus, the aggressive nature of TNBC coupled with
a significant toxicity and suboptimal outcomes of the current
therapies necessitate development of new and effective TNBC
treatment strategies. We seek to develop nanoparticle-based
strategies for improving TNBC radiation therapy outcome.
Therefore, we investigated the capacity of AuNPs to enhance
the effect of a single dose of RT in TNBC MDA MB 231 tumor
model. Since TNBC outcome is greatly influenced by the ability
of host immune system to develop antitumor response, we also
examined AuNPs’ effects on immunological properties of
MDA MB 231 tumor microenvironment (TME).
Therapeutic potential of AuNPs strongly depends on nano
particles size, shape, and functional modification. These
important parameters affect nanoparticles in vivo circulation
half-life, biodistribution, tumor uptake, and toxicity.
Particularly important are the level of AuNPs cellular uptake

and intracellular localization and proximity to various orga
nelles/compartments, since these can profoundly influence
magnitude and type of cellular responses to stress, such as
ionizing irradiation or AuNP itself. It has been shown that
AuNPs with diameters of 10–30 nm exhibited optimal char
acteristics with regard to circulation half-life and intratumor
accumulation and diffusion.42 Conversely, larger nanoparticles
(>50 nm) were associated with a lower uptake by tumors and
probable capture by liver, while smaller nanoparticles
(<10 nm) were more readily excreted by kidneys.8,43 At the
cellular level, intermediate size AuNPs (10–50 nm) were shown
by most studies to exhibit the greatest uptake,43,44 while smaller
AuNPs (<5 nm) need to aggregate to be endocytosed.43,45 On
the other hand, once inside the cell smaller AuNPs generate
more ROS than larger AuNPs, due to larger surface area to
volume ratios.46,47 In addition to AuNP size, surface modifica
tion also has an important role in AuNPs therapeutic potential.
Surface coating with PEG has been commonly used to stabilize
and prolong AuNPs’ circulation half-life and intratumor
distribution,42,48 however the same PEG coating was also
shown to decrease the level of AuNPs cellular uptake and the
production of ROS needed for AuNPs radio-sensitization to
take place.18,49 Considering all these factors we opted to use
spherical AuNPs of 4 nm and 14 nm in size, surface capped by
a monolayer of mercaptosuccinic acid (MSA). Our previous
work using identical nanoparticle preparations demonstrated
no cytotoxicity in vitro and no toxicity in vivo.15,50–52 In agree
ment with our previous report on MCF-7 breast cancer cells,15
in this study both 4 nm and 14 nm size AuNPs were success
fully taken up by MDA MB 231 cells without changes in their
cellular morphology. Both size AuNPs were found inside the
cytoplasmic vesicles (endosomes and lysosomes) that were
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detected in the vicinity of mitochondria, endoplasmic reticu
lum and nuclei. It is of note that 14 nm AuNPs were found in
the nuclei as well. It was previously proposed that nuclear
import via the nuclear pore complex is expected for nanopar
ticles of less than 30 nm in diameter,53 while particles smaller
than 9 nm enter the nuclei by passive diffusion.54 However, in
our current study using MDA MB 231 cells and our previously
published work in MCF-7 cells, 4 nm AuNPs were found in the
cytoplasm only with no presence in the nuclei. As mentioned,
AuNPs smaller than 5 nm in size need to aggregate to be
endocytosed,43,45 therefore, it is possible that aggregation of
4 nm AuNPs resulted in larger complexes that were incompa
tible with nuclear transport. However, the actual mechanisms
explaining the observed nuclear 14 nm AuNP localization
remain unresolved. Similar to our findings, nuclear AuNPs
localization was reported in MCF-7 after endocytosis of
15.6 nm size PEG-coated AuNPs.55 Then again, in MDA MB
cell lines previous work implicates various factors, such as
sedimentation rate, diffusion speed, irregular morphology,
and concentration of aggregates playing a role in AuNPs’
cellular uptake and trafficking.32,56 In summary, an explanation
of the mechanisms for the observed nuclear 14 nm AuNP
localization require further investigation. Our data shown
here agree with previous, limited number of studies exploring
AuNPs’ therapeutic potential in human breast cancer cell lines.
These studies showed cellular uptake and localization within
the endosome/lysosome compartment for PEG coated and
functionalized small (5 nm) and large (100 nm) AuNPs in
MDA MB 231 cells30,57 and for 10.8 nm “naked” and 15.6 nm
PEG-modified AuNPs in MCF-7 cell line.9,55 As shown by
previous work, the level of cellular uptake and intracellular
localization have significant impact on AuNP induced oxida
tive stress and enhancement of radio sensitization.19,44
Particular intracellular AuNPs localization as well as proximity
to various organelles and compartments may govern the type
and magnitude of cellular responses to stressors such as ioniz
ing irradiation or AuNPs alone. For a maximum DNA damage
to take place, AuNPs nuclear localization is desired where close
proximity to DNA would maximize the effectiveness of photo
electric effect at low radiation energies as well as the damaging
effect by AuNP’s ROS production and induced chemical
sensitization.3,58 On the other hand, sufficient evidence
demonstrated that nuclear localization is not necessary for
AuNPs radio sensitization and that sole close proximity to
crucial cellular components may facilitate stress and damage
by ROS and short-range low energy electrons produced by
AuNP alone or under low radiation energy, respectively.17,18
Organelles or compartments undergoing stress elicit signaling
cascade for programmed cell death execution. However, the
type of the cell death initiated (apoptosis vs. ICD) will depend
on what organelle or cell compartment death signal originates
from and will affects the magnitude of overall tissue damage
and inflammatory and immune response.37,59 Therefore, our
findings on different intracellular localization indicate that
nanoparticle size-dependent differences in AuNPs mediated
RT enhancement observed in in vivo experiments may be due
to a difference in observed intracellular localization between
4 nm and 14 nm AuNPs that dictated different magnitude and

129

temporal occurrence of DNA damage, mitochondrial and ER
stress as underlying mechanisms of cell death initiation.
Radio sensitization by AuNPs have been evaluated in
numerous in vivo studies. However, many critical parameters,
such as tumor model, AuNPs administration dose and route,
RT dose and dosing schedule of AuNPs and RT, varied across
these studies with still no consensus on optimal condition for
the best therapeutic outcome. Various tumor models have been
used to investigate AuNP radiosensitizing potential using
a broad range of AuNP doses, with total intratumor AuNPs
levels varying between 0.25 ug to 70 mg of gold per gram of
tumor.8,60–67 In the current study we used 100 ug per tumor
that resulted in detectable therapeutic effect with 14 nm AuNP
alone and enhancement of RT effect with both 4 nm and 14 nm
AuNPs. Previous studies indicated that systemic, intravenous
administration of AuNPs delivers less than 7% of injected dose
to the tumor site due to their capture by organs such as liver
and spleen, which may cause systemic toxicity.68,69 To avoid
AuNPs entrapment by liver and spleen and potential systemic
toxicity, and to maximize AuNPs accumulation at the tumor
site,30,60 the current study employed direct intratumor AuNPs
injection. To ensure nanoparticles availability within the tumor
as well as their cellular uptake, AuNPs were administered 24 h
prior to irradiation. Most of the reported in vivo work evaluat
ing AuNPs radiosensitization effects utilized a single adminis
tration of a high irradiation dose (5–50 Gy) since a detectable
therapeutic response is expected to be observed within that
range in a majority of available tumor models.14,18,60,70 Various
reasonings behind the dose of choice have been provided;
however, a clear mechanistic justification and consensus on it
has yet to be offered. Studies by Hainfeld et al. suggested that at
low doses AuNPs may not exhibit therapeutic improvement,
while high doses may elicit toxicity.70 Thus, an effective dose
for assessing AuNPs potential to enhance RT would be below
the toxicity threshold but high enough to induce therapeutic
response. Based on our previous work and our experience with
different tumor models we opted to use a single high RT dose
of 15 Gy.71 In a clinical setting administration of a single high
dose of RT in BC patients was explored mainly as
a preoperative procedure.72,73 However, most clinical BC pro
tocols consist of fractionated regimens of lower RT doses,
indicating the need for future exploration of AuNPs potential
using fractionated low RT doses, also suggested to provide
superior conditions for AuNP radio sensitization.65 On the
other hand, breakthroughs with stereotactic ablative body
radiotherapy (SABR) showing that precisely administered
high RT doses in a small number of fractions doubled median
survival for oligometastatic disease74 and significantly
increased the response rate to cancer immunotherapy,75 open
the possibility for a clinical AuNPs application at high RT
doses as well. Our experiments reported here based on the
use of a single high RT dose delivered significant radiation
enhancement effect with 4 nm and 14 nm AuNPs. In the
absence of radiation both 4 nm and 14 nm AuNPs induced
significant tumor growth delay compared to that of the
untreated control group. This effect was equivalent to RT
alone treatment in mice receiving 4 nm AuNPs, and to RT +
AuNPs in mice receiving 14 nm AuNPs. However, treatments
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with 4 nm AuNPs alone or in combination with RT exhibited
an observable, though not significant, systemic toxicity, which
was absent in animals receiving 14 nm AuNP. Since small size
AuNPs previously demonstrated increased potential in ROS
production even in the absence of radiation,3,46 it is possible
that intra and extracellular pathways triggered by this property
played a role in the observed toxicity. Significant radiation
enhancement evaluated by survival was achieved with 14 nm
AuNPs alone or in combination with RT. At the same time,
4 nm AuNPs did not deliver overall survival significance.
Failure of 4 nm AuNPs to show statistically significant RT
enhancement measured by overall survival may be due to
a heterogeneous distribution of AuNPs within the tumor
volume, as opposed to more homogenous distribution of
14 nm AuNPs, as observed on macroscopic cross sections of
tumor tissues. Previously, this limited and unequal tumor
penetration has been observed often with intratumor injections
and it is most likely due to nanoparticle aggregation30,60 that
may also impact intracellular uptake and may explain the
observed lack of nuclear entrance of 4 nm AuNPs. Similar to
our results, the study by Cui et al. using MDA MB 231 xeno
grafts in mice showed that small, 7 nm RME-PEG-AuNPs
failed to confer significant RT enhancement using an intratu
mor injection of 0.5 mg of AuNP,30 despite the utilization of
RME targeted AuNPs delivery and fractionated 3 × 4 Gy RT
regimen that were likely to enhance AuNPs effects. Since with
heterogenous intratumor distribution some AuNPs most likely
remain in extracellular matrix, it is possible that we only
observed a trend in RT enhancement with smaller size
AuNPs because AuNPs that reside outside of the cells were
less effective.19 However, further studies are needed to evaluate
and confirm the effect of AuNPs size and modifications on
intratumor distribution. Consistent with our observation,
Chattopadhyay et al. demonstrated using similar in vivo
TNBC xenograft model that intratumor injection of 30 nm
HER-2 tagged AuNPs delivered significant enhancement of
a single 11 Gy RT dose effect as measured by tumor growth
delay, without detecting any systemic toxicity.60 However, it is
important to note that their experimental design differed from
our study in that we used nonmodified AuNPs and eight times
smaller AuNPs dose (0.8 mg/tumor vs. 0.1 mg/tumor). In
addition, a scarcity of AuNPs RT enhancement studies using
TNBC models and utilized diverse experimental conditions,
challenge a direct comparison of results across studies.
Classical radiobiology defines mitotic cell death as a loss of
replicative capacity that is determined by clonogenic assays.76
Over the last decade, other RT induced cell death have been
identified. For example, ICD, as a form of RT-induced regu
lated cell death (RCD), has emerged as an entity separate from
other immunologically silent RCDs or apoptosis and has been
implicated to play a role in governing disease progression and
outcome, partially through affecting host antitumor immune
response.59 Despite its inherent immunological limitations,
immunodeficient mouse model does allow for an assessment
of tumor cells ICD and the host macrophage immune
response.77,78 We examined ICD by evaluating the levels of
damage-associated molecular patterns (DAMPs) molecule cal
reticulin, an ER chaperone that is translocated to the cell sur
face in response to stress in a process considered to be a pre-

apoptotic or pre-ICD event37,59,79 and it may be initiated by
AuNP induced ER stress even without RT.10 Calreticulin, as
well as other DAMPs, activate phagocytic and the antigenpresenting cells of an innate immune response, such as macro
phages and dendritic cells and possibly drive adaptive antitu
mor immunity.37 In addition to calreticulin, we evaluated the
level of cleaved Caspase 3 as well, as a mean to assess total levels
of RT induced apoptosis. Our findings revealed that both 4 nm
and 14 nm AuNPs delivered significant enhancement of RT
effect at the level of calreticulin expression. Interestingly,
14 nm AuNPs alone significantly increased calreticulin expres
sion as well. On the other hand, the levels of RT-induced
activated Caspase 3 were not enhanced by addition of either
size AuNPs to RT. It is considered that RDC involving
Caspase-3 activation is generally not immunogenic80 and
under our experimental condition most likely entail mitochon
drial apoptotic pathway that is activated by radiation-induced
DNA damage.81 Since post irradiation DNA damage seemed to
be directly linked to intracellular AuNPs presence and physical
effects at the time of irradiation,82 this mechanism may par
tially be responsible for the observed RT enhancement in
tumor growth delay after addition of 4 nm and 14 nm AuNP.
However, onset of the tumor growth delay enhancement with
14 nm AuNP was detected earlier than with the addition of
4 nm AuNP and the effect of AuNP alone was greater with
14 nm AuNPs compared to 4 nm AuNPs. Together with the
observation that 4 nm AuNP did not enhance RT-induced
survival, it is probable that effects of 14 nm AuNPs involve
additional, cell death mechanisms. The increase in calreticulin
expression and related ICD may partially account for the effect
of 14 nm AuNP alone, but it does not support the differences
between 4 nm and 14 nm RT therapeutic enhancements.
Calreticulin acts on CD91 receptors on phagocytic cells to
attract, promote and activate phagocytosis of dying cells.59
However, corresponding data on macrophage infiltration
demonstrated significant increase only in group receiving RT
+ 14 nm AuNP. In addition to calreticulin signaling, macro
phages can response to ICD by interacting with other DAMPs
such as nuclear chromatin-binding protein HMGB1 and ATP
through engagement of their TLR4 and purinergic receptors,
respectively.83 Therefore, our calreticulin data may not accu
rately represent the post-treatment ICD levels. Since the DNA
damage is a most prominent RT and AuNP enhanced RT
effect, it is possible that nanoparticle size differential effect on
ICD may be detected by differences in HMGB1 nuclear protein
and will necessitate further investigation. In addition, the com
plexity of immunological cascade triggered by ICD in response
to RT and its enhancement by AuNPs supersedes the investi
gative capacity of xenograft nude mouse model used here and
will require immunocompetent environment to further analyze
antigen-presenting and T cell response components.
In summary, here we demonstrated in vivo significant RT
enhancement that was achieved by intratumor AuNPs admin
istration, evident by both tumor growth delay and overall
survival. These effects were nanoparticle size-dependent with
14 nm AuNPs delivering therapeutic enhancement. We show,
that underlying mechanism in addition to cytotoxicity involve
immunological changes as well. Further dissection of these
immunological properties will be valuable in understanding
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mechanisms of AuNPs driven events in TNBC that may be
relevant in developing multimodal radio therapies that may
include radiosensitizers as well as immunotherapy. In addition,
experimental platform used in this work can be applied as
a model for studying AuNPs mechanisms in cancer types
other than TNBC.

Materials and methods
Mice
Seven to 8-week old athymic nude NCRNU f sp/sp (CrTac:
NCr-Foxn1nu) mice were purchased from Taconic Biosciences,
and maintained in the AAALAC approved animal facility of
the institutional Bioresources division. Mice were kept under
pathogen-free conditions. Animal experiments were per
formed according to the protocol approved by Institutional
Animal Care and Use Committee, IACUC # 1648.
Cell line and reagents
Human breast cancer MDA MB 231 cells were purchased from
American Type Culture Collection (ATCC) (Manassas, VA).
Cells were cultured in DMEM supplemented with 10% fetal
bovine serum, 2 mmol/L L-glutamine, 100 U/ml penicillin, 100
ug/ml streptomycin, all purchased from Invitrogen/Thermo
Fisher Corporation. Cells were maintained in a tissue culture
incubator at 37°C with 5% CO2. Cells were passaged every
3–4 days and cultured to limited passage and implanted while
at the exponential phase of growth.
Gold nanoparticle (AuNP) synthesis and characterization
Gold nanoparticles were synthesized according to our pre
viously published method.15 Briefly, materials used for synth
esis were as follows: Gold (III) chloride trihydrate (HAuCl4
· 3H2O, 99% metal trace), sodium citrate tribasic dehydrate
(≥99%), mercaptosuccinic acid (MSA, 97%), and sodium bor
ohydride (NaBH4, 98%) (all from Sigma-Aldrich) and sodium
hydroxide (NaOH, 98%) (Fisher Scientific). Synthesis of MSA
coated AuNP with diameter of 4 nm (AuNP4) started with
a 250 ml scale reaction involving a mixture of 0.25 � 10−3
M HAuCl4 · 3H2O and 0.25 � 10−3 M tri-sodium citrate in
deionized water, vigorously stirred at room temperature.
Addition of 7.5 mL ice cold 0.1 M NaBH4 solution changed
the color of the solution into wine-red. After 30 min of stirring,
pH was adjusted to 11 and 25 mg of MSA was added. To ensure
complete ligand exchange the solution was continuously stir
red for overnight. The solution was then purified and concen
trated by centrifugation, using MW 10 K Millipore Amicon
columns, followed by 3 washes with deionized water to remove
impurities and reagents carried over from the synthesis. The
final concentration in deionized sterile water was 2 mg/ml.
MSA-coated AuNP with diameter of 14 nm (AuNP14) was
synthesized following the Turkevich method.84–86 In a typical
250 ml scale reaction, 0.25 � 10−3 M HAuCl4 · 3H2O was
dissolved in deionized water and then heated to boil under
vigorous stirring. Preheated 87.5 mg of trisodium citrate dis
solved in 15 mL deionized water was then added. After the
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color changed to wine-red, heating was continued for 25 min
while stirring. Solution was then cooled down; the pH was
adjusted to 11 and 25 mg of MSA added. Solution was then
stirred overnight to ensure the complete ligand exchange after
which it was purified and concentrated to the final concentra
tion of 2 mg/ml using the same steps as for 4 nm AuNP. Upon
completion of AuNPs synthesis, NPs were analyzed using JEOL
JEM-2010 Transmission Electron Microscope (TEM) at the
voltage of 200kV and current of 109 mA. Energy dispersive
x-ray analysis (EDXA) spectrum was acquired on EDAX
PV9756/70 ME EDS system attached to the TEM. Dynamic
light scattering (DLS) and zeta potential measurements were
performed using a Malvern Nano-ZS. The same AuNP pre
paration was previously used in in vitro and15,50 and in vivo
conditions with no associated toxicity51,52 .
Cell exposure to AuNPs
Twenty four hours prior to the exposure to AuNPs, MDA MB
231 cells were plated in 6 well cell culture dishes with total of
3–5 × 105 cells per well. Cells were cultured o/n in a tissue
culture incubator at 37°C with 5% CO2. The next day cell were
treated for 2 h with either 4 or 14 nm AuNPs in a complete
growth media. Fifty µl of AuNPs at the concentration of 2 mg/
ml was added to the 1 ml of growth media with a final con
centration of 100 ug/ml. Expressed as particles per ml the final
concentration for the 4 nm AuNPs was 3.12 × 1013 particles/
ml, while for the 14 nm AuNP the concentration was 7.2 × 1011
particles/ml.
Analysis of AuNP cellular uptake by transmission electron
microscopy (TEM)
A total of 5 × 105 cells were plated in 6 well cell culture plates
and cultured for 24 h. Cells were then exposed for 3 h to
AuNPs. Four nm size AuNPs were added at the concentrations
of 3.12 × 1013 p/ml, while 14 nm size AuNPs were used at
7.2 × 1011 p/ml. Following exposure to AuNPs, cells were
washed twice in 1x phosphate-buffered saline (PBS), and pre
pared for TEM as previously described.50 In brief, cells were
fixed in in 2.5% glutaraldehyde in 0.1 M Phosphate Buffer, pH
7.4 (Electron Microscopy Sciences, Hatfield, PA) for 1 h at
room temperature. Cells were then scraped of the plates, cen
trifuged at a low speed and suspended in 2.5% glutaraldehyde.
Samples were further processed at the Michigan State
University (MSU) Center for Advanced Microscopy by postfixation in 1% osmium tetroxide, rinsing in distilled water, and
dehydration through a graded series of acetone. At the end,
samples were embedded in epoxy resin and cut into 70 nm
sections that were then analyzed and photographed by JEOL
100CXII electron microscope.
Tumor implantation and treatment
For implantation, 2 × 106 of MDA MB 231 cells were sus
pended in 100 ul of sterile saline and were injected intramus
cularly into the right flank of nude mice. Tumors were
measured at 3–4 days intervals by determining perpendicular
tumor diameters using external caliper and tumor volumes

132

B. JANIC ET AL.

were calculated using the following formula: 4∕3π x Length
x Width x ((Length + Width)/2)/8. Two weeks later, when
tumors were palpable and grew to the average volume of
433 mm3, mice were randomly assigned to different treatment
groups as described. First, animals received intratumor injec
tion of 4 or 14 nm AuNPs at the concentration of 2 mg/ml. To
minimize the leakage of the injected volume, AuNP were
administered via multiple different injection sites (typically,
four) to a total volume of 50 µl. Twenty-four hours after
receiving AuNPs, mice were irradiated with 15 Gy dose at
160kV using an x-ray source (Faxitron small animal irradia
tor). Radiotherapy was administered as previously described.71
Briefly, mice were anesthetized with the mixture of Ketamine
(200 mg/kg) and Xylazine (20 mg/kg) via i.p. injection. Mice
were positioned on a plexiglas tray, their entire bodies pro
tected by lead shield except for the area of the tumor to be
irradiated. Radio sensitization effect was assessed by determin
ing tumor growth delay and animal survival. Tumor growth
was evaluated every 3–4 days until day 36 as described above.
All animals were euthanized by day 36 and the tumors excised
and prepared for immunohistochemistry analysis.
Immunohistochemistry analysis
Harvested tumor tissue collected at day 15 underwent immu
nohistochemistry analysis. Tissues were processed routinely
for 7 hours through formalin, graded ethanol alcohol, xylene
and paraffin, using a VIP Tissue Tek automated tissue pro
cessor. The FFPE blocks were sectioned at 4 µm on a Microm
Manual Microtome, using low profile disposable blades. The
sections were mounted on Autofrost IHC slides (Fisher
Scientific) to ensure the sections adhered to the slide during
staining. The sections were left to dry on a drying rack over
night and placed in the 60°C incubation oven for 1 h. The
slides were deparaffinized with xylene and rehydrated
through a series of descending alcohols to water. The tissue
slides underwent 20 min incubation with Envision FLEX
(Agilent) low pH target retrieval solution in a Dako PT
Linker at 97°C. The slides were placed on the Dako
Autostainer Link and the following sequence was followed:
The slides were blocked with Peroxidaze 1 (PX968H, Biocare
Medical) for 5 min. The following primary antibodies and
dilutions were used: anti-Calreticulin, 1:15000 for 20 min
(Sino Biological, 13539-T60), anti-cleaved Caspase 3, 1:250
for 20 min (Cell Signaling, 9579S) and anti- F4/80 antibody,
1:500 dilution (Cell Signaling, 70076). The slides were then
incubated for 30 min with Envision FLEX HRP (K8004Agilent) mixed with XM Factor (XMF963C, Biocare
Medical), and 10 min in Envision FLEX DAB (K8000,
Agilent). Slides were then counterstained with Hematoxylin
(K8008, Agilent) for 5 min, dehydrated through a series of
alcohols, cleared in xylene and cover slipped with nonaqueous mounting medium. Images were captured by using
Leica Aperio CS2 slide scanner. The positive cells stained
brown. The slides were examined under a light microscope,
and representative digital images were taken from
a minimum of 3 slides from each animal. Digitalized tissue
stains were evaluated for staining extent and intensity by
QuPath software87 custom made application. The staining

extent is quantified as the number of positive pixels divided
by the total number of tissue pixels, where the positive pixels
are defined as pixels with positive staining optical density
(OD) above threshold of 0.25. The staining intensity was
presented by the average positive stain OD that was used as
a measurement of the biomarker expression.
Statistical analysis
Experiments using 4 and 14 nm AuNP were performed sepa
rately, each including their own internal controls. The change
of tumor volume (TV) after treatment was normalized as
percentage of the initial TV (POITV) before treatment
(day 0). POITV was measured at indicated time intervals.
The change in the body weight after treatment was normalized
as percentage of the initial body weight before treatment
(day 0). Tumor volume change and body weight change data
were analyzed using unpaired Student’s t-test, with a statistical
significance considered at the p < .05 level. For 4 nm AuNP
experiments, n = 5 and for 14 nm AuNP, n = 5–9, as indicated
in Table 3. Survival time analysis was performed by Kaplan
Meier log-rank test followed by Gehan-Breslow-Wilcoxon test
for differences in survival between two treatment groups. For
immunohistochemistry analysis, tissues harvested from 3 ani
mals per group that were sacrificed at day 15 were analyzed.
For each mouse, 3 histology slides and 5 fields per slide were
analyzed. The quantified average staining OD and staining
percentage or percent of positive cells was used as an immune
biomarker expression measurement. One-way ANOVA exam
ined the expression difference across treatments. Analysis was
performed using GraphPad Prism6 (San Diego, CA).
Significance was set at the p value of 0.05.
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